Trial Profile
Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Dapagliflozin (Primary) ; Empagliflozin (Primary) ; Losartan (Primary) ; Pentoxifylline (Primary) ; Semaglutide (Primary) ; Spironolactone (Primary) ; Telmisartan (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 23 Feb 2022 New trial record